Back

Digital PCR-based deep quantitative profiling delineates heterogeneity and evolution of uveal melanoma

Nell, R. J.; Versluis, M.; Menger, N. V.; Verdijk, R. M.; Kroes, W. G. M.; Kapiteijn, E. H. W.; Luyten, G. P. M.; Jager, M. J.; van der Velden, P. A.

2024-02-02 ophthalmology
10.1101/2024.01.30.24301871 medRxiv
Show abstract

Uveal melanoma is an aggressive intraocular tumour characterised by a limited number of genetic alterations. However, the evolution of this malignancy remains enigmatic. In this study, we performed a deep quantitative analysis of 80 primary uveal melanomas by novel digital PCR-based approaches. Mutations were quantified by targeted and drop-off mutation assays, copy number alterations were precisely measured by quantifying the allelic imbalance of heterozygous single-nucleotide polymorphisms. By comparing the absolute abundances of genetic alterations present in a bulk tumour, the heterogeneity and early evolution could be inferred. Tumour progression was further studied by analysing matched primary and metastatic lesions from five patients. Gq signalling mutations were generically and always clonally present, suggesting to be acquired in the earliest stage of uveal melanoma development ( primary driver). Next, three main evolutionary subtypes could be identified based on having an EIF1AX mutation, SF3B1 mutation or monosomy 3p. These alterations were usually mutually-exclusive and (near-) clonally abundant, suggesting to represent distinct secondary drivers. This contrasts with gains and amplifications of chromosome 8q, which were not restricted to one of the main subtypes and showed subclonality in 31% of the affected tumours. These tertiary alterations were not required for metastatic dissemination. Using high-resolution analyses, we identified systematic differences in the evolutionary timing of genetic events in uveal melanoma. The observed intratumour heterogeneity suggests a more complex model of gradual tumour evolution and argues for a comprehensive genetic analysis in clinical practice, which may be facilitated by the sensitive digital PCR assays developed in this study.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
The Journal of Pathology
26 papers in training set
Top 0.1%
22.5%
2
Angiogenesis
14 papers in training set
Top 0.1%
12.0%
3
British Journal of Cancer
49 papers in training set
Top 0.1%
9.0%
4
Journal of Medical Genetics
29 papers in training set
Top 0.1%
5.5%
5
PLOS ONE
5266 papers in training set
Top 31%
4.9%
50% of probability mass above
6
Nature Communications
5641 papers in training set
Top 34%
3.5%
7
Cancers
213 papers in training set
Top 2%
3.2%
8
Scientific Reports
3612 papers in training set
Top 33%
3.2%
9
eLife
5828 papers in training set
Top 35%
3.2%
10
Acta Neuropathologica Communications
89 papers in training set
Top 0.9%
2.1%
11
Genome Medicine
183 papers in training set
Top 2%
2.1%
12
Ophthalmology Science
22 papers in training set
Top 0.2%
1.9%
13
BMC Genomics
406 papers in training set
Top 4%
1.9%
14
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.3%
1.7%
15
Molecular Oncology
55 papers in training set
Top 0.6%
1.7%
16
EMBO Molecular Medicine
95 papers in training set
Top 2%
1.1%
17
JCI Insight
277 papers in training set
Top 6%
1.1%
18
Oncogene
85 papers in training set
Top 1%
1.1%
19
Communications Biology
993 papers in training set
Top 24%
1.1%
20
Frontiers in Oncology
103 papers in training set
Top 3%
0.9%
21
Clinical Cancer Research
64 papers in training set
Top 2%
0.9%
22
OncoImmunology
24 papers in training set
Top 0.6%
0.9%
23
Frontiers in Endocrinology
58 papers in training set
Top 2%
0.6%
24
Gut
40 papers in training set
Top 1.0%
0.6%
25
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.6%
26
Cell Genomics
172 papers in training set
Top 4%
0.6%
27
JCO Precision Oncology
14 papers in training set
Top 0.4%
0.6%
28
Cell Reports
1498 papers in training set
Top 29%
0.6%
29
Modern Pathology
22 papers in training set
Top 0.5%
0.6%